GI Alliance Launches MASLD Clinical Trials at Two Dallas-Fort Worth Locations
The nation's leading gastroenterology network, GI Alliance, has initiated clinical trials for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at two strategic locations in the Dallas-Fort Worth metroplex, marking a significant advancement in liver disease research and treatment accessibility.
The trials will be conducted under the leadership of Dr. Harry Sarles at Digestive Health Associates of TX – Rockwall and Dr. Moustafa Youssef at Digestive Health Associates of TX – Mansfield. These studies represent a crucial step forward in addressing a growing health concern that affects approximately 25% of the U.S. population.
Disease Burden and Clinical Significance
MASLD, previously known as Nonalcoholic Fatty Liver Disease, has emerged as a significant public health challenge, affecting nearly 100 million Americans. The condition is characterized by excessive fat accumulation in liver cells, with normal liver fat content being below 5-10% of the organ's weight. Of particular concern is its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), which can lead to liver inflammation and impaired organ function.
"Clinical trials are the key to making innovative medications available to a large national audience and also offer hope to patients living with serious chronic conditions like MASLD or MASH," explains Dr. Youssef, highlighting the trials' potential impact on treatment development.
Trial Implementation and Patient Access
Dr. Sarles emphasizes the trials' accessibility, stating, "We are thrilled to offer patients the opportunity to participate in clinical trials near home in the comfort of a practice they trust." This local availability removes traditional barriers to clinical trial participation, potentially accelerating research outcomes.
The trials are open to participants aged 18 and above who have received their MASLD or MASH diagnosis at least three months prior to enrollment. Current GI Alliance patients interested in participating can access more information through a dedicated hotline.
Research Network Capabilities
GI Alliance's extensive network, comprising over 800 independent gastroenterologists across 400 practice locations in 16 states, provides robust infrastructure for conducting these trials. The organization's commitment to clinical research, combined with its practice management support and knowledge-sharing capabilities, positions these trials to potentially influence future treatment protocols significantly.
The network's approach integrates clinical research with patient care management strategies, ensuring that findings can be efficiently translated into improved treatment outcomes. This systematic approach to research and care delivery exemplifies GI Alliance's dedication to advancing gastroenterological care while maintaining high standards of clinical practice.